Osteoarthritis is a chronic progressive disease where there is degeneration & loss of articular cartilage that occurs together with new bone formation at the joint surfaces and margins, that causes pain and deformity.
The patient experiences pain, stiffness, decreased movement, inflammation and crepitus.
The pain is usually aggravated by pain and relieved by rest.
Partial knee replacement surgery provides similar clinical outcomes as total knee replacement in patients with late-stage osteoarthritis (OA), although the former proves more cost-effective according to the results of the TOPKAT* trial.
Interleukin-1 inhibition with lutikizumab does not yield substantial analgesic or anti-inflammatory effects in the treatment of patients with knee osteoarthritis (OA) and associated synovitis, with the results of a phase II trial showing limited improvement in pain and synovitis.
The antinerve growth factor fasinumab delivers significant analgesic effects in patients experiencing moderate-to-severe pain from osteoarthritis, including those benefitting little from a previous analgesic, according to the results of a phase IIB/III trial.
Greater parity, early age at menarche, or oral contraceptive use may increase a woman’s risk of undergoing total knee replacement (TKR) for severe knee osteoarthritis (OA), according to findings from the Singapore Chinese Health Study (SCHS).
Inhibition of interleukin-1 with lutikizumab falls short in the treatment of patients with knee osteoarthritis, with the results of a phase II study showing that the drug yields limited reductions in pain without any improvement in synovitis.
The coexistence of fibromyalgia in patients with axial spondyloarthritis (axSpA) exerts a negative effect on response to tumour necrosis factor blocker, according to a study. This effect appears to be associated with the self-reported instruments used in fibromyalgia evaluation rather than a different treatment effect of the agent in this population.